FAQ: Soligenix Expands European Medical Advisory Board for HyBryte Phase 3 Study in Cutaneous T-Cell Lymphoma

What is the main announcement from Soligenix in this content?

Soligenix has expanded its European Medical Advisory Board to guide the confirmatory Phase 3 trial of HyBryte for early-stage cutaneous T-cell lymphoma.

What is HyBryte and what condition does it treat?

HyBryte (SGX301 or synthetic hypericin sodium) is a novel photodynamic therapy that uses safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

When are the top-line results expected for the Phase 3 study?

Top-line results from the Phase 3 study are expected in the second half of 2026.

How many patients will be enrolled in the Phase 3 trial?

The 18-week Phase 3 study is enrolling about 80 patients with early-stage cutaneous T-cell lymphoma.

Why is Soligenix expanding its European Medical Advisory Board?

The expansion strengthens European engagement ahead of potential commercialization of HyBryte following successful completion of the Phase 3 study.

What other development programs does Soligenix have in its Specialized BioTherapeutics segment?

Other programs include expansion of synthetic hypericin into psoriasis, dusquetide for inflammatory diseases including oral mucositis, and treatments for Behcet’s Disease.

What is Soligenix’s Public Health Solutions business segment focused on?

This segment includes vaccine programs for ricin toxin, filoviruses (Marburg and Ebola), and CiVax for COVID-19 prevention, using their proprietary ThermoVax heat stabilization technology.

How is Soligenix’s Public Health Solutions segment funded?

This segment has been supported with government grant and contract funding from NIAID, DTRA, and BARDA.

Where can investors find the latest news and updates about Soligenix?

The latest news and updates relating to SNGX are available in the company’s newsroom at https://ibn.fm/SNGX

What is the significance of this Phase 3 trial for Soligenix?

This confirmatory Phase 3 trial is crucial as successful completion will support regulatory approvals for potential worldwide commercialization of HyBryte for cutaneous T-cell lymphoma.